A new study suggests that patients with relapsing–remitting multiple sclerosis can experience long-term increases in disability in the absence of disease relapses. Monitoring this ‘silent progression’ will require a paradigm shift in the way disease progression is evaluated.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
University of California, San Francisco MS-EPIC Team et al. Silent progression in disease activity–free relapsing multiple sclerosis. Ann. Neurol. 85, 653–666 (2019).
Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444–1452 (1983).
Fischer, J. S. et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult. Scler. 5, 244–250 (1999).
Goodin, D. S. et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 83, 282–287 (2012).
University of California, San Francisco MS-EPIC Team et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann. Neurol. 80, 499–510 (2016).
Filippi, M. et al. Gray matter damage predicts the accumulation of disability 13 years later. Neurology 81, 1759–1767 (2013).
Radue, E. W. et al. Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology 84, 784–793 (2015).
Kappos, L. et al. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult. Scler. 22, 1297–1305 (2016).
Lorscheider, J. et al. Defining secondary progressive multiple sclerosis. Brain 139, 2395–2405 (2016).
Rocca, M. A. & Filippi, M. Targeting progression in multiple sclerosis — an update. Nat. Rev. Neurol. 15, 62–64 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.F. is Editor-in-Chief of the Journal of Neurology; has received compensation for consulting services and/or speaking activities from Biogen, Merck Serono, Novartis and Teva Pharmaceutical Industries; and receives research support from ARiSLA (Fondazione Italiana di Ricerca per la SLA), Biogen, Fondazione Italiana Sclerosi Multipla, the Italian Ministry of Health, Merck Serono, Novartis, Roche and Teva Pharmaceutical Industries. M.A.R. received speaker honoraria from Biogen, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis and Teva Pharmaceutical Industries; and receives research support from Fondazione Italiana Sclerosi Multipla and the Italian Ministry of Health.
Rights and permissions
About this article
Cite this article
Filippi, M., Rocca, M.A. Classifying silent progression in relapsing–remitting MS. Nat Rev Neurol 15, 315–316 (2019). https://doi.org/10.1038/s41582-019-0199-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-019-0199-8
